CJC-1295
Human PK data for DAC form; Common confusion between DAC and no-DAC
Brief Overview: CJC-1295 is a growth-hormone-releasing hormone analog. The single most important distinction is whether the product has DAC. No-DAC products behave like short GHRH pulses; DAC products bind albumin and last for days. Evidence lens: The DAC version has human pharmacokinetic data showing a multi-day half-life. Many community protocols, however, actually refer to modified GRF 1-29/no-DAC while calling it CJC. Confusing these two can lead to wrong expectations about accumulation, side effects, and monitoring. How to read this: if you're new, verify the exact molecule before reading any protocol. Once you're past the basics, distinguish GH pulsatility from prolonged “GH bleed,” because the endocrine risk profile is different.
- CJC-1295 is a synthetic tetrasubstituted 29-amino acid peptide hormone, specifically acting as a Growth Hormone-Releasing Hormone (GHRH) analog.
- It was developed by ConjuChem Biotechnologies to treat muscle wasting and growth hormone deficiencies.
- It is a modified version of GRF (1-29) (Sermorelin), engineered for superior stability and a significantly longer half-life.
- CJC-1295 needs a DAC/no-DAC distinction every time. DAC forms are long-acting albumin-binding GHRH analogs; No-DAC or modified GRF(1-29)-type products behave much more like short-acting pulse agents.
CJC-1295 stimulates the pituitary gland to increase the endogenous production of Growth Hormone (GH):
- GHRH Receptor Agonism: It binds to GHRH receptors on the somatotroph cells in the anterior pituitary, triggering the synthesis and pulsatile release of GH.
- IGF-1 Elevation: Increased GH levels prompt the liver to produce Insulin-like Growth Factor 1 (IGF1), which mediates most of the peptide’s anabolic and recovery effects.
- Pulsatile Preservation: Unlike synthetic HGH, CJC-1295 (specifically the “No DAC” version) preserves the body’s natural “pulses” of growth hormone rather than shutting down natural production.
- DAC Technology: The “With DAC” (Drug Affinity Complex) version incorporates a maleimide group that binds to circulating albumin, preventing enzymatic degradation and extending its activity from minutes to days.
- The mechanism is pituitary GHRH-receptor stimulation, increasing GH pulses and downstream IGF-1. It is not the same as giving growth hormone directly, and physiologic reserve limits response. The mechanism here is a plausibility map, not proof of a clinical outcome.
- The strongest human evidence is pharmacokinetic/pharmacodynamic: CJC-1295 with DAC can produce prolonged GH and IGF-1 elevation after dosing.
- DAC and no-DAC products must be separated. DAC produces multi-day exposure; No-DAC/modified GRF behaves more like a short GHRH pulse.
- Body-composition, sleep, and injury-repair claims are often discussed in clinics and communities, but they are not established outcomes for every CJC-1295 product without direct study context.
- The exact molecule, DAC status, dose interval, and monitoring plan need to be clear before any claimed benefit means much.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions.
- Protocol 1: CJC-1295 (No DAC / MOD-GRF) [Research/Experimental]; Route: Injection, fasted; Dose: 100 mcg – 200 mcg; Frequency: 1 to 3 times daily; Timing: Fasted (AM or before bed); Duration: 8 to 12 weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: CJC-1295 (With DAC) [Research/Experimental]; Route: Injection; Dose: 2,000 mcg (2 mg); Frequency: Once weekly; Timing: Any time (long-acting); Duration: 8 to 12 weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Dosing must identify DAC status. 5-on/2-off logic is not pharmacokinetically meaningful for DAC forms, while short-acting forms are often used in pulse-style protocols with ipamorelin. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: No-DAC about 2.5 hours; DAC about 4-6 weeks.
- Half-life basis: No-DAC/modified GRF: roughly 30 minutes; CJC-1295 DAC: 5.8-8.1 days in a human study.
- Beginner translation: This estimate uses the standard four-to-five-half-life convention. It describes when plasma exposure would be expected to approach a plateau during repeated dosing, not when the desired outcome is complete.
- Practical interpretation: Always state whether the product is no-DAC/modified GRF or DAC; The steady-state timelines are completely different.
- Delivery: Subcutaneous (SC) injection is the standard. Oral versions are generally considered to have poor bioavailability for this specific peptide chain.
- Route note: do not generalize intranasal/oral findings across GH secretagogues. Older GHRP-2 and hexarelin data, animal ipamorelin nasal PK, and community sermorelin/CJC nasal-buccal products are different evidence categories.
- DAC CJC-1295 has multi-day activity; No-DAC forms have short exposure. This is one of the clearest examples where a peptide name without modifier status can break a calculator. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- Ipamorelin: The standard, reliable stack. Pairing a GHRH (CJC) with a GHRP (Ipamorelin) creates a much larger GH release than either peptide used alone.
- BPC-157: Often added for advanced injury rehabilitation protocols.
- Common pairing with ipamorelin combines GHRH and ghrelin/GHS-R signaling. This is mechanistically plausible, but combining GH-axis agents increases IGF-1, edema, glucose, sleep-apnea, and carpal-tunnel-type monitoring needs. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
”CJC Flush”: Many users experience a temporary rush of heat and redness in the face/neck immediately after injection; The exact mechanism is not well characterized, and it should not be attributed cleanly to the GH pulse.
- Water Retention: Can cause mild edema (swelling) or joint tingle if the dose is too high.
- Contraindications: Should be avoided by anyone with active cancer or a history of pituitary tumors, as GH can accelerate cell growth.
- Watch for flushing, tachycardia, edema, numbness/tingling, headache, glucose changes, and excessive IGF-1. Flushing is not a harmless sign that the GH pulse worked. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- Serum IGF-1: The primary marker used to verify that the peptide is working and the dose is appropriate.
- Fasting Glucose/HbA1c: Growth hormone can affect insulin sensitivity; Long-term users should monitor blood sugar levels.
- Prolactin: In rare cases, some GHRH analogs can slightly elevate prolactin.
- Track IGF-1 against age-adjusted range, fasting glucose/A1c, edema, blood pressure, sleep apnea symptoms, carpal tunnel symptoms, and injection reactions. Glucocorticoids, obesity, sleep, and nutrition can alter response. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- FDA: CJC-1295 was removed from the Category 2 “do-not-compound” list in September 2024 after nominators withdrew the original nomination. It remains under FDA review and is expected to be referred to the Pharmacy Compounding Advisory Committee at a future meeting (date not yet announced). It is not FDA-approved for any indication. This is a distinct regulatory trajectory from the 12 peptides covered by the April 15, 2026 HHS action.
- WADA: Banned under S2 (Peptide Hormones and Growth Factors).
- Availability: Continues to be compounded in practice during the review period; Check with your pharmacy on current legal status.
- CJC-1295 is not FDA-approved, and FDA has flagged serious adverse events and characterization concerns for compounded CJC-1295. DAC/no-DAC identity matters in regulatory and quality discussions. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.